Deep vein thrombosis
Overview
•Virchow's triad - venous stasis, endothelial injury, hypercoagulability; most DVTs involve >1 element
•Calf veins most common site; proximal propagation (popliteal, femoral) significantly increases PE risk
Risk factors
Immobility / prolonged travel
Recent surgery or trauma
Malignancy
Combined OCP / oral HRT
Pregnancy / gravid uterus
Thrombophilia (e.g. Factor V Leiden, protein C/S deficiency)
Antiphospholipid syndrome
Dehydration / heart failure
IV catheters / chemotherapy
Previous VTE
Presentation
•Unilateral calf/leg pain, swelling, pitting oedema, erythema and warmth, dilated superficial veins
•Calf circumference >3 cm difference (measured 10 cm below tibial tuberosity) is significant
•Many DVTs are asymptomatic and first present as PE
Investigations
•Two-level DVT Wells score - stratifies into DVT likely (≥2) or DVT unlikely (<1); guides whether to image first or use D-dimer
•D-dimer - sensitive (~95%) but non-specific; negative result excludes DVT when Wells score is low; false positives: pregnancy, malignancy, infection, surgery, heart failure, recent trauma
•Proximal leg Doppler ultrasound - first-line imaging; non-compressibility of the vein is the diagnostic criterion
•Repeat ultrasound at 6-8 days - if initial ultrasound negative but D-dimer positive and Wells score suggests DVT likely
•Thrombophilia testing - consider in unprovoked/recurrent DVT, strong family history, or unusual site; do NOT test during acute thrombosis or anticoagulation
•Malignancy screen - consider in unprovoked DVT: clinical examination, FBC, LFTs, urinalysis as minimum
Differential diagnosis
Management
•Anticoagulation is the mainstay of treatment - typically a DOAC (rivaroxaban or apixaban) as first-line per NICE NG158
•Unprovoked DVT carries higher recurrence risk - consider longer anticoagulation and investigation for underlying malignancy or thrombophilia
Prevention
•All inpatients should be assessed for VTE risk on admission and individual bleeding risk weighed against benefit of prophylaxis (NICE NG89)
•First-line pharmacological: enoxaparin (LMWH) - start as soon as possible and within 14 hours of admission
•First-line mechanical: anti-embolic compression stockings - used alongside LMWH in surgical patients; contraindicated in significant peripheral arterial disease, severe leg oedema, or skin breakdown
•Second-line mechanical: intermittent pneumatic compression devices - if stockings contraindicated or for additional prophylaxis in high-risk surgical patients
•Early mobilisation and adequate hydration - important for all inpatients
Complications
•Pulmonary embolism - most life-threatening; massive PE causes cardiovascular collapse; smaller PE: pleuritic chest pain, dyspnoea, haemoptysis
•Post-thrombotic syndrome - up to 50% within 2 years; chronic venous obstruction and valve destruction → persistent venous hypertension → oedema, pain, dermatitis, venous ulceration
•Recurrent DVT - higher risk in unprovoked DVT and thrombophilia